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A B S T R A C T
B cell CLL/lymphoma 6 member B (BCL6B) is a novel tumor suppressor silenced in human cancer. In this
study, we investigated the functional role and underlying mechanisms of BCL6B in hepatocellular car-
cinoma (HCC). BCL6B was expressed in normal HCC tissues, but its expression was suppressed in 6 out
of 9 HCC cell lines. Loss of BCL6B expression was associated with promoter hypermethylation. Ectopic
expression of BCL6B in HepG2 and Huh7 cell lines inhibited colony formation (P < 0.05), cell viability
(P < 0.01), and tumorigenicity in nude mice (P < 0.05). BCL6B expression also induced apoptosis (P < 0.05),
an effect associated with activation of the caspase cascade and cleavage of PARP. Stable expression of
BCL6B in MHCC97L cells suppressed cell migration (P < 0.05) and invasion (P < 0.05), and signiﬁcantly
reduced the incidence and severity of lung metastasis in an orthotopic HCC mouse model. The anti-
metastatic effect of BCL6B was mediated by up-regulation of cell adhesion gene E-cadherin, OB-
cadherin, HIV-1 Tat interactive protein 2, and transient receptor potential cation channel, subfamily M,
member 1; and down-regulation of angiogenesis gene VEGFA. BCL6B functions as a tumor suppressor
that inhibits HCC metastases in vitro and in vivo.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Hepatocellular carcinoma (HCC) is the third most fatal malig-
nancy with rapidly increasing incidence worldwide. Although some
advances in therapeutic strategies for HCC patients have
been achieved since the introduction of sorafenib as a ﬁrst line
chemotherapy, prognosis remains poor due to high rates of recur-
rence and metastasis [1,2].
An aberrant epigenetic landscape is a common hallmark of human
cancers. Although the molecular mechanisms underlying the patho-
genesis of HCC remain elusive, the epigenetic inactivation of tumor
suppressor genes through promoter DNA hypermethylation has been
increasingly recognized to play a crucial role in the development
of this disease [3]. Several tumor suppressor genes, including UCHL1
[4] and PAX5 [5], have been identiﬁed by us to be epigenetically si-
lenced in HCC via promoter hypermethylation. Identiﬁcation of novel
tumor suppressor genes silenced by promoter methylation in HCC
is a highly informative approach to understand the mechanism of
carcinogenesis and metastasis; and to unravel biomarkers useful for
the diagnosis and prognosis of the disease.
BCL6B, also known as BAZF, ZNF62 and ZBTB28, belongs to the
BCL6 gene family and it functions as a sequence-speciﬁc transcrip-
tional repressor in the nucleus [6,7]. BCL6B is ubiquitously expressed
in human tissues with abundant expression in the heart and pla-
centa [8]. It is well documented that BCL6B plays an important role
in spermatogonial stem cell self-renewal [9]. Ectopic expression of
BCL6B inhibited gastric cancer growth via the induction of
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apoptosis and the inhibition of cell proliferation [6]. However, the
expression pattern and the potential role of BCL6B in HCC remain
unclear.
In the present study, we ﬁrst demonstrated a frequent loss of
BCL6B expression in HCC cell lines due to promoter DNA
hypermethylation. Both in vitro and in vivo functional studies re-
vealed that the ectopic expression of BCL6B resulted in signiﬁcant
suppression of HCC cell proliferation, invasion and metastasis. Our
results indicate that BCL6B functions as a novel tumor suppressor
in HCC by inducing apoptosis and inhibiting metastasis.
Materials and methods
Human HCC cell lines and tissue samples
Ten human HCC cell lines (HepG2, Hep3B, PLC-5, Huh1, Huh6, Huh7, Bel7404,
SNU398, SNU449 and MHCC97L) were obtained from ATCC. MHCC97L stably ex-
pressing luciferase was a gift from Man K, Department of Surgery, the University
of Hong Kong [10]. The cells weremaintained in DMEMmedium (Gibco BRL, Rockville,
MD) with 10% fetal bovine serum, penicillin (50 unit/ml) and streptomycin (50 μg/
ml) at 37 °C with 5% CO2. Primary tumor and their adjacent non-tumor tissues were
obtained from 40 HCC patients during operation prior to any therapeutic interven-
tion from the Third Aﬃliated Hospital of Sun Yat-sen University. All of the samples
were subsequently veriﬁed by histology. Informed consent was given to all the pa-
tients. The study protocol was approved by the Clinical Research Ethics Committee
of Sun Yat-Sen University.
RNA extraction, semi-quantitative reverse-transcription-PCR and real-time
PCR analyses
Total RNA was extracted from HCC cell lines and tissue samples using Trizol
reagent (Invitrogen, Carlsbad, CA). Complementary DNA was synthesized from total
RNA using Transcriptor Reverse Transcriptase (Roche Applied Sciences, Indianapo-
lis, IN). For semi-quantitative reverse-transcription-PCR, BCL6B gene was ampliﬁed
using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), with
β-actin as internal control (add reference). Real-time PCR was performed using SYBR
Green master mixture on an HT7900 system (Applied Biosystems). Primer se-
quences are listed in Supplementary Table S1.
Methylation-speciﬁc PCR (MSP) and Bisulﬁte sequencing (BGS)
Genomic DNA was extracted from the HCC cell lines using QIAamp DNA Mini
kit (Qiagen, Hilden, Germany). DNA was chemically modiﬁed with sodium
metabisulphite. The bisulﬁte-modiﬁed DNAwas ampliﬁed by using primers that spe-
ciﬁcally amplify either methylated or unmethylated sequences of the BCL6B gene
(Supplementary Table S1). Bisulﬁte-modiﬁed DNA was ampliﬁed by PCR using BGS
primers [6] and sequenced.
5-Aza-2′-deoxycytidine treatment
HepG2, Hep3B and Huh7 cell lines with silenced BCL6B expression were treated
with vehicle or 2 mM DNA demethylating agent 5-aza-2′-deoxycytidine (Sigma-
Aldrich, St Louis, MO) for 5 days. 5-Aza-2′-deoxycytidine was replenished every day.
Cell viability assay
7.5 × 103 cells in 100 μl complete medium were seeded into each well of a 96-
well plate and incubated overnight. Cell viability was then determined using Vybrant
MTT Cell Proliferation Assay Kit according to themanufacturer’s protocol (Invitrogen).
Absorbance at 592 nm was measured on a microplate reader and cell growth was
calculated after subtraction of blank values.
Colony formation assay
HepG2 and Huh7 cells were transfected with expression plasmids pcDNA3.1-
HA-BCL6B or the empty vector pcDNA3.1 using lipofectamine 2000 (Invitrogen). Forty-
eight hours post transfection, cells were collected and seeded (3 × 103/well) in six-
well plates for 10–14 days. Colonies (≥50 cells/colony) were then ﬁxed with 70%
ethanol, stained with crystal violet solution, and counted.
Apoptosis assay
Apoptosis was determined by staining cells with Annexin V and 7-amino-
actinomycin (7-AAD) (BD Biosciences) with subsequent ﬂow cytometry analysis.
In vivo tumorigenicity
HepG2 cells (1 × 107 cells in 100 μl PBS) transfectedwith BCL6B or pcDNA3.1 vector
were injected subcutaneously into the dorsal left ﬂank of 4-week-old male Balb/c
nude mice (5 mice in each group). Tumors were measured every 3 days for 2 weeks
with a microcaliper. Tumor volumes (mm3) were estimated bymeasuring the longest
and shortest diameters of the tumors and calculated as previously described [11].
All experimental procedures were approved by the Animal Ethics Committee of the
Chinese University of Hong Kong.
Tumor cells migration assay
HepG2, Huh7 or MHCC97L cells, with or without ectopic expression of BCL6B,
were seeded in six-well plates. Sterile tips were used to scratch cell layers, which
were washed with PBS, and cultured in complete DMEM medium. Cells were pho-
tographed (phase-contrast microscope) after incubation for 0, 24, and 48 h,
respectively. The distance travelled by cells was measured between the two bound-
aries of a cellular area. Each experiment was performed in triplicate.
Tumor cells invasion assay
Invasion assay was performed using BD BioCoatTM Growth Factor Reduced
MATRIGELTM Invasion Chamber (BD Biosciences) according to the manufacturer’s
instructions. Brieﬂy, HepG2, Huh7 or MHCC97L cells, with or without ectopic ex-
pression of BCL6B, were seeded onto the membrane of the upper chamber in serum-
free DMEM. The lower chamber was ﬁlled with complete DMEM medium as
chemoattractant. After 48 h, cells that had invaded through the Matrigel mem-
brane were stained with crystal violet, counted under an inverted microscope and
photographed. All experiments were conducted in triplicate.
Tube formation assay
Conditioned medium were collected by incubating Lenti-BCL6B and Lenti-
vector control infected MHCC97L cells without serum for 24 h. Each well of a 96-
well plate was coated with 50 μl diluted Matrigel (Millipore, Billerica, MA) and
incubated at 37 °C for 1 h to allow the Matrigel to polymerize. 1 × 104 HUVEC cells
were seeded into each well and incubated with 100 μl conditioned DMEM plus 1%
fetal bovine serum-in a CO2 incubator for 16 h to allow the formation of tube-like
structures. Image analysis of tube length was carried out using Image software (NIH
website, USA).
Lentivirus packaging and transduction
To construct a lentivial vector for BCL6B, the BCL6B expression plasmid used in
our previous study [6] was digested with SalI and EcoRI and then cloned into the
SalI/EcoRI sites of pU6 [12]. The U6-BCL6B cassette with EcoRI and ClaI from pU6
was cut out by double digestion and subcloned into EcoRI/ClaI sites of the lentiviral
vector LUNIG [12]. The sequence of the inserted fragment was veriﬁed by DNA se-
quencing. The lentivirus was produced by co-transfecting 293T cells with the transfer
vector and three packaging vectors [12]. Subsequent puriﬁcation was performed by
ultracentrifugation. Cells were plated in 24-well plates and transduced with lentivirus
in the presence of 8 μg/ml polybrene (Sigma, St. Louis, MO).
Orthotopic murine liver tumor model of distant metastasis
An orthotopic HCC metastasis mouse model was established using MHCC97L,
which has the potential to metastasize to the lungs [10]. MHCC97L cells (2 × 106 cells
in 0.1 ml PBS) transduced by BCL6B-lentivirus (Lenti-BCL6B) and empty vector-
lentivirus (Lenti-vector) were injected subcutaneously into the left dorsal ﬂank of
4-week-old male Balb/c nude mice, respectively. Subcutaneous tumors were har-
vested once they reached about 10 mm3 and cut into 1.0 mm3 pieces. One piece of
a tumor was then implanted into the left liver lobe in a separate group of nude mice
(6-week-old) (seven per group) [10]. Eight weeks after tumor implantation, the mice
were sacriﬁced and examined. The lungs were dissected and paraﬃn embedded, and
the sections were stained with hematoxylin and esosin. Metastatic tumors were
counted in a blinded manner. All experimental procedures were approved by the
Animal Ethics Committee of the Chinese University of Hong Kong.
cDNA expression array
Gene expression proﬁles were analyzed using the Human Tumor Metastasis PCR
Array according to the manufacturer’s protocol (SABiosciences, Frederick, MD). Data
were analyzed using SABiosciences software. Genes with fold-changes more than
or less than 1.5 were considered to be of biological signiﬁcance.
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Western blot analysis
Total protein was separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. Blots were
probed with primary antibody and then with secondary antibody. Proteins of in-
terest were visualized using ECL Plus Western blotting detection reagents (RPN2132,
GE Healthcare, Piscataway, NJ).
Statistical analysis
Data are presented as means ± SD. Multiple group comparisons were analyzed
by one-way ANOVA after Bonferroni’s correction. Non-parametric data between two
groups were computed by chi-square test or Fisher exact test. The difference between
two different groups was determined by Student’s t-test. P-values < 0.05 were con-
sidered statistically signiﬁcant.
Results
BCL6B is down-regulated in human HCC cell lines
We ﬁrst compared themRNA expression of BCL6B in normal liver
tissues and nine HCC cell lines including HepG2, Hep3B, PLC5, Huh1,
Huh6, Huh7, Bel7404, SNU398, and SNU449 (Fig. 1A). We found that
BCL6B expression was notably repressed in six out of the nine tested
HCC cell lines as compared with normal liver tissues. Western blot
analysis conﬁrmed the loss of BCL6B protein expression in HCC cell
lines (Fig. 1C).
Down-regulation of BCL6B expression is associated with
advanced HCC
We examined the expression of BCL6B in 40 pairs of HCC samples,
including 20 early stage (TNM I and II) and 20 advanced stage (TNM
III and IV) HCCs (Fig. 1B). We found that BCL6B expression was sig-
niﬁcantly down-regulated in stage III and IV HCC tumors as compared
with adjacent normal tissues (P < 0.01). There were no signiﬁcant
difference in BCL6B expression between tumors and their adja-
cent normal tissues in stage I and II HCCs. These ﬁndings suggest
that the down-regulation of BCL6B is associated with advanced HCC
with invasive and/or metastatic potential.
Correlation of BCL6B mRNA expression level with methylation status
in HCC cell lines
We evaluated the association between the silencing of BCL6B and
promotermethylation status in HCC cell lines byMSP and BGS. Heavy
methylation of the BCL6B promoter was observed in all six HCC cell
lines in which BCL6B was silenced (Fig. 1A). These results suggest
a close correlation between BCL6B mRNA expression and its meth-
ylation status in HCC cell lines.
To further conﬁrm that DNA methylation is indeed res-
ponsible for the silencing of BCL6B, three HCC cell lines, HepG2,
Hep3B and Huh7, were treated with a demethylation agent
Fig. 1. Transcriptional silencing of BCL6B in HCC is associated with DNA methylation. (A) BCL6B expression was determined by RT-PCR. BCL6B was silenced in many HCC
cell lines (upper left). Methylation of BCL6B was determined by methylation speciﬁc PCR (MSP) (lower left) and bisulﬁte sequencing (BGS) (right). (B) BCL6B mRNA expres-
sion was determined by quantitative real-time PCR in 40 pairs of early (TNM stage I/II) and advanced (TNM stage III/IV) HCC. A signiﬁcant reduction in BCL6B mRNA expression
was observed in advanced HCC tumors as compared with their adjacent normal tissues. (C) The protein expression of BCL6B in HCC cell lines and normal liver tissues was
determined by western blot. (D) The mRNA expression of BCL6B was restored after treatment with demethylation agent 5-Aza.
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5-aza-2′-deoxycytidine (5-Aza). Expression of BCL6B was dramat-
ically restored after 5-aza treatment in all three HCC cell lines
(Fig. 1D). The addition of trichostatin A, a HDAC inhibitor, did not
increase BCL6B mRNA expression compared with 5-aza alone
(Supplementary Fig. S1), further conﬁrming that promoter DNA
methylation mediated the transcriptional silencing of BCL6B.
BCL6B suppresses HCC cell growth
HepG2 and Huh7 cells were transfected with pcDNA3.1-BCL6B
or empty pcDNA3.1 vector (control) for 48 h. Ectopic expression of
BCL6B was conﬁrmed by RT-PCR andWestern blot (Fig. 2A). Cell vi-
ability (MTT) assay demonstrated that the overexpression of BCL6B
signiﬁcantly suppressed cell growth comparedwith control (P < 0.01;
Fig. 2B) in both HCC cell lines. The growth suppressive effect of BCL6B
was further conﬁrmed by the reduced colony formation eﬃciency
in BCL6B-overexpressed HCC cells relative to control cells (P < 0.05;
Fig. 2C).
BCL6B induces apoptosis in HCC cells
To determinewhether the observed growth suppression by BCL6B
overexpression was due to the induction of apoptotic cell death,
BCL6B overexpressing cells and control cells were stained with
Annexin V/7-AAD and analyzed by ﬂow cytometry. Ectopic expres-
sion of BCL6B in both HepG2 and Huh7 cells resulted in a signiﬁcant
increase of apoptotic cell population as compared with control
(P < 0.05; Fig. 3A). We then performedWestern blot analysis on these
cells to assess the expression of apoptosismarkers, including caspase-
7, caspase-3 and poly (ADP-ribose) polymerase (PARP). Consistent
with an increased induction of apoptosis, our results showed that
BCL6B induced the expression of cleaved caspase-7, caspase-3 and
PARP in both HepG2 and Huh7 cell lines (Fig. 3B).
Fig. 2. BCL6B overexpression inhibits the growth of HCC cells. (A) Ectopic expression of BCL6B in Huh7 and HepG2 cell lines was conﬁrmed by RT-PCR and western blot.
(B) Cell viability was reduced by overexpression of BCL6B in Huh7 and HepG2 cells. (C) Ectopic expression of BCL6B suppressed colony formation.
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BCL6B inhibits tumor growth in nude mice
To conﬁrm the tumor suppressive effect of BCL6B in HCC, we as-
sessed whether BCL6B overexpression could suppress the growth
of HCC cells in nudemice in vivo. The tumor growth curves of HepG2
cells stably transfected with BCL6B or empty vector in nude mice
are shown in Fig. 3C. The mean tumor volume was signiﬁcantly
smaller in nude mice implanted with BCL6B-transfected cells than
that with the vector control-transfected cells (P < 0.01), indicating
that BCL6B acts as a tumor suppressor in HCC.
BCL6B suppresses HCC cell migration and invasion
We next investigated the effect of BCL6B on HCC cell migration
and invasion using themonolayer scratch healing assay andMartrigel
invasion assay, respectively. Ectopic expression of BCL6B marked-
ly slowed the migration ability of HepG2, Huh7 and MHCC97L cells
(Fig. 4A). Quantitative analyses at 48 h conﬁrmed a signiﬁcant re-
duction in wound closure in BCL6B-expressed cells compared with
control cells (Fig. 4A) in all three HCC cell lines. In addition, BCL6B
also signiﬁcantly impaired the invasiveness of HepG2, Huh7 and
MHCC97L cells in the Martrigel invasion assay (Fig. 4B).
BCL6B reduces angiogenesis in vitro
The effect of BCL6B on the angiogenesis of HCC cells was deter-
mined by human umbilical vein endothelial cell (HUVEC) tube
formation assay. As shown in Fig. 5, conditioned culture medium
from BCL6B-transfected Huh7 and HepG2 cells signiﬁcantly reduced
the tube-forming capacity of HUVEC on Matrigel as compared with
that from control vector-transfected cells (P < 0.05), which indi-
cates that BCL6B decreased the secretion of pro-angiogenic factors
from HCC cells.
BCL6B inhibits HCC metastasis to the lungs in vivo
Since cell migration and invasion and angiogenesis are crucial
during themetastatic process, we investigated whether BCL6B could
alter the metastatic potential of MHCC97L cells in vivo in an ortho-
topic metastasis mouse model. In this model, subcutaneously grown
Fig. 3. BCL6B induced cell apoptosis and inhibited tumor growth in nude mice. (A) BCL6B induced apoptosis in Huh7 and HepG2 cells, as determined by ﬂow cytometry
analysis following Annexin V and 7-AAD staining. The upper panel represents FACS images of HCC cells transfected with empty vector or BCL6B, while the lower panel
shows the quantitative analyses of early apoptotic and late apoptotic cells. The experiment was repeated three times in triplicate. Data are mean ± SD. (B) Protein expres-
sion of the active forms of apoptosis related genes caspase 3, caspase 7, and poly (ADP-ribose) polymerase (PARP) was evaluated by Western blot. GAPDH was used as a
loading control. (C) Ectopic expression of BCL6B inhibited the growth of subcutaneous HepG2 xenografts in nude mice.
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xenografts derived fromMHCC97L cells expressing luciferase were
implanted into the livers of nude mice. Eight weeks after surgery,
tumor inoculation in the liver was conﬁrmed by xenogen imaging
(Fig. 6A). Histological examination of the lungs showed that 85.7%
(6/7) of the mice bearing Lenti-vector transduced MHCC97L cells
exhibited lung metastases after orthotopic implantation (Fig. 6B).
In contrast, only 14.3% (1 out of 7) of the animals bearing Lenti-
BCL6B transduced MHCC97L cells developed lung metastases
(P < 0.05). Therefore, these data provide strong evidence that BCL6B
inhibits lungmetastasis of orthotopically implanted HCC cells in vivo.
BCL6B modulates the expression proﬁles of metastasis-related genes
in MHCC97L cells
To evaluate the molecular mechanisms underlying the inhibi-
tory effect of BCL6B on HCC cell metastasis, gene expression proﬁles
in Lenti-BCL6B transduced MHCC97L cells were analyzed using a
human tumor metastasis pathway PCR array. Compared with Lenti-
vector transduced cells, BCL6B overexpressing cells showed profound
alterations in genes involved in cell to cell adhesion, cell growth,
and cell metastasis, all of which are critical to the regulation of cancer
cell invasiveness andmetastasis (Table 1). Of note, the overexpression
of BCL6B signiﬁcantly increased the expression of cell adhesion genes
including E-cadherin (3.3-fold), and OB-cadherin (1.6-fold) and two
metastasis suppressors, HIV-1 Tat interactive protein 2 (HTATIP2)
(3.1-fold) and transient receptor potential cation channel, subfam-
ily M, member 1 (TRPM1) (1.8-fold), whereas the expression of key
pro-angiogenic factors such as vascular endothelial growth factor
A (VEGFA) (-1.5-fold) were suppressed. To validate these altera-
tions, Western blot was performed on HepG2, Huh7 and MHCC97L
cells with or without overexpression of BCL6B. Consistent with the
results from the PCR array, BCL6B increased the protein expres-
sion of E-cadherin and OB-cadherin with a concomitant diminution
of VEGFA in all three HCC cell lines (Fig. 6C).
Fig. 4. Effect of BCL6B on HCC cell migration and invasion. (A) Representative result of scratch healing assay. (B) Representative result of invasion assay. The experiment
was repeated three times in triplicate. Data are mean ± SD.
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Discussion
We investigated the epigenetic regulation of BCL6B in HCC
and addressed its role in HCC progression and metastasis. We
observed that BCL6B is highly expressed in normal human liver
tissues but is silenced in seven out of nine HCC cell lines evalu-
ated. The reduced expression of BCL6B is associated with promoter
methylation. BCL6B gene inactivation in HCC cell lines as
Fig. 5. Effect of BCL6B on angiogenesis. The effect of BCL6B on angiogenesis was evaluated by the tube formation assay. HUVEC cells were incubated in culture medium
conditioned with (A) HepG2 and (B) Huh7 cells transfected with control vector or BCL6B. In both cell lines, ectopic expression of BCL6B resulted in a signiﬁcant reduction
in tube formation by HUVEC cells.
Fig. 6. Enhanced expression of BCL6B suppressed HCC metastasis to lung in vivo. (A) Tumors derived from the luciferase-labelled MHCC97L cells were successfully im-
planted orthotopically into the livers of nude mice and tumors can be detected in all the mice after 8 weeks. Tumor growth in the mice was monitored by a live imaging
system. (B) Lung metastasis of the HCC mice with or without BCL6B overexpression at 8 weeks after orthotopic implantation. The lung metastatic nodules were analyzed
histologically. Quantitative analyses showed the lung metastasis incidence in Lenti-BCL6B group was signiﬁcantly lower than that in the Lenti-Vector group. (C) Western
blots were performed to validate the downstream gene expression regulated by BCL6B in HepG2, Huh7 and MHCC97L. GAPDH was used as an internal control.
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compared with normal liver tissues suggests that BCL6B could act
as a tumor suppressor and its down-regulation may contribute to
the development and progression of HCC. We therefore assessed
the putative tumor suppressor function of BCL6B in HCC. As ex-
pected, ectopic expression of BCL6B in HepG2 andHuh7 cells resulted
in a signiﬁcant growth-suppressive effect, manifested in de-
creased cell viability and anchorage independent growth. The tumor
suppressive effect of BCL6B was conﬁrmed in vivo, as evidenced by
the diminished growth of BCL6B expressing HCC cells in nude mice.
Underlying the growth inhibitory effect of BCL6B is a robust apoptotic
response. In HepG2 and Huh7 cells, BCL6B overexpression signiﬁ-
cantly induced apoptosis via the up-regulation of cleaved caspase-
3, caspase-7 and poly (ADP-ribose) polymerase 1 (PARP1). The
cleavage of PARP1 causes loss of DNA repair, cellular disassembly
and ﬁnally apoptosis [13,14]. Collectively, these results indicate that
the BCL6B gene functions as a tumor suppressor in HCC.
Metastasis is a major cause of death from cancers. Here, we are
the ﬁrst to demonstrate that the epigenetic silencing of BCL6B may
contribute to the metastatic capacity of HCC via a triad of mecha-
nisms: the promotion of (1) cell migration, (2) cell invasion, and (3)
angiogenesis. Correspondingly we showed that ectopic expres-
sion of BCL6B in three HCC cell lines (HepG2, Huh7 and MHCC97L)
inhibited their metastatic activity in vitro. BCL6B overexpression also
inhibited lung metastases in vivo in an orthotopic HCC xenograft
model. Hence, our ﬁndings indicate that the re-expression of BCL6B
signiﬁcantly suppresses the metastatic potential of HCC and its epi-
genetic silencing may conversely accelerate HCC metastasis in
humans. Indeed, analysis of paired HCC patient tumors and their
adjacent normal tissues revealed that there is a speciﬁc down-
regulation BCL6B mRNA expression in advanced HCC (TNM stages
III and IV), which is largely consistent with our hypothesis that BCL6B
acts as a metastatic suppressor in human HCC.
Gene expression proﬁling further revealed insights into poten-
tial molecular mechanisms involved in BCL6B-mediated anti-
metastatic effect in HCC. On the basis of our array data (Table 1) and
subsequent validation by Western blot, it appears that the anti-
metastatic effect of BCL6B is mediated via the up-regulation of cell
adhesionmolecules E-cadherin and OB-cadherin. E-cadherin, a cell–
cell adhesion molecule, is a key component of epithelial adherent
junctions. Loss of E-cadherin expression is a hallmark of epithelial-
to-mesenchymal (EMT) transition, a critical step that allows cancer
cells to gain migratory and invasive properties, thus leading to me-
tastasis [15–17]. OB-cadherin, on the other hand, has also been
reported to inhibit migration of osteosarcoma cells in vitro and at-
tenuate their ability to metastasize to the lungs in an in vivo
spontaneous metastasis model [18]. Thus, the simultaneous up-
regulation of E-cadherin and OB-cadherin by BCL6B contributes to
its anti-metastatic effect in HCC. Our array analysis also revealed
that BCL6B expression is associated with a decrease in VEGFA ex-
pression. Angiogenesis is essential for the growth of solid tumors
as well as metastatic spread, and VEGFA is the primary factor driving
the expansion of the tumor vascular bed [19]. Hence, the growth
inhibitory and anti-metastatic effect of BCL6B in vivo is mediated,
at least in part, by an antiangiogenic effect that involves suppres-
sion of VEGFA signaling. BCL6B overexpression also up-regulates the
expression of two metastasis suppressors, HTATIP2 and TRPM1. It
has reported that the down-regulation of HTATIP2 augments
hepatocarcinogenesis [20] and contribute to sorafenib-induced HCC
invasiveness and metastasis [21]. Accordingly, the epigenetic si-
lencing of HTATIP2 by promoter methylation is associated with poor
prognosis in HCC patients [22]. On the other hand, TRPM1 expres-
sion correlates inversely with metastasis and survival in melanoma
[23]. Hence, the tumor suppressive effect in HCC may be medi-
ated via the up-regulation of anti-metastatic genes and down-
regulation of angiogenic factors.
In conclusion, we have identiﬁed BCL6B as a novel tumor sup-
pressor gene in HCC that is silenced by promoter methylation.
Consistent with the tumor suppressive function of BCL6B, BCL6B
suppresses the invasive and metastatic potential of HCC in vitro and
in vivo. BCL6Bmay be a potential target for the prevention and treat-
ment of HCC metastasis.
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